Ipsen Medical Director
Ipsen · Ipsen Consumer Healthcare
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Ipsen Medical Director as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:57 UTC. Showing 200 of 286. Open this list on ClinicalTrials.gov
- N/ANCT07906639 · A Study of Fatigue, Itching and Daily Activities in People With Primary Biliary Cholangitis Starting ElafibranorIpsen · not yet recruiting · Primary Biliary Cholangitis (PBC) · study director
- N/ANCT07588880 · A Study of the Effectiveness, Safety and the Long-term Outcomes of Participants With Progressive Familial Intrahepatic Cholestasis (PFIC) Who Take Odevixibat (Bylvay) in ChinaIpsen · recruiting · Progressive Familial Intrahepatic Cholestasis · study director
- N/ANCT07585097 · A Study to Observe the Long-term Safety of Odevixibat in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing TreatmentIpsen · recruiting · Alagille Syndrome · study director
- N/ANCT07556913 · Elafibranor Pregnancy Surveillance Program: A Study to Evaluate the Safety of Elafibranor During PregnancyIpsen · recruiting · Pregnancy Related · study director
- N/ANCT07497724 · Odevixibat Outcomes in Patients With PFIC Versus an External Control Cohort (OvEC-PFIC)Ipsen · active not recruiting · PFIC - Progressive Familial Intrahepatic Cholestasis · study director
- Ph1NCT07441707 · A Study to Assess a Medicine Called Tovorafenib in Japanese Children and Young Adults With Brain TumoursIpsen · active not recruiting · Low-grade Glioma · study director
- Ph3NCT07427797 · A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between the EyebrowsIpsen · active not recruiting · Moderate to Severe Glabellar Lines · study director
- Ph3NCT07387549 · A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing CholangitisIpsen · recruiting · Primary Sclerosing Cholangitis · study director
- N/ANCT07314164 · Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior TreatmentIpsen · recruiting · Neuroendocrine Tumors · study director
- N/ANCT07282548 · Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two TherapiesIpsen · withdrawn · Follicular Lymphoma · study director
- Ph1/Ph2NCT07213830 · A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor TherapiesIpsen · recruiting · Advanced Solid Tumor, Metastatic Solid Tumor · study director
- Ph1/Ph2NCT07213817 · A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid TumoursIpsen · recruiting · Locally Advanced Solid Tumor, Metastatic Solid Tumor · study director
- N/ANCT07191704 · A Study to Assess the Genetic Variations in Bile Flow Disorders: Linking Progressive Familial Intrahepatic Cholestasis (PFIC)-Related Genes to Symptoms in Adults With Recurrent Cholestasis in SpainIpsen · completed · PFIC - Progressive Familial Intrahepatic Cholestasis · study director
- N/ANCT07185919 · A Study of the Effectiveness, Safety and the Long-term Outcomes of Participants With Progressive Familial Intrahepatic Cholestasis (PFIC) Who Take Odevixibat (Bylvay) in South KoreaIpsen · recruiting · Progressive Familial Intrahepatic Cholestasis · study director
- N/ANCT07049887 · A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria)Ipsen · completed · Primary Biliary Cholangitis · study director
- Ph2NCT06937931 · A Study of IPN10200 for the Treatment of Cervical Dystonia in AdultsIpsen · recruiting · Cervical Dystonia · study director
- Ph1NCT06908954 · A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single DoseIpsen · completed · Hepatic Impairment, Healthy · study director
- N/ANCT06850038 · A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing TreatmentIpsen · recruiting · Alagille Syndrome · study director
- Ph1/Ph2NCT06833008 · A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid TumoursIpsen · active not recruiting · Advanced Solid Tumor · study director
- Ph3NCT06730061 · A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC)Ipsen · active not recruiting · Primary Biliary Cholangitis · study director
- Ph2NCT06625060 · A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in AdultsIpsen · active not recruiting · Episodic Migraine, Chronic Migraine · study director
- N/ANCT06447168 · A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing TreatmentIpsen · active not recruiting · Primary Biliary Cholangitis · study director
- Ph3NCT06383403 · A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.Ipsen · completed · Primary Biliary Cholangitis · study director
- Ph2NCT06341712 · Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With OsteosarcomaIpsen · terminated · Osteosarcoma, Osteosarcoma in Children, Osteosarcoma in Adolescents and Young Adults · study director
- Ph1/Ph2NCT06305247 · A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid TumoursIpsen · active not recruiting · Melanoma, Head and Neck Squamous Cell Carcinoma, Pancreatic Ductal Adenocarcinoma · study director
- N/ANCT06258902 · Odevixibat Pregnancy and Lactation Surveillance Program: A Study to Evaluate the Safety of Odevixibat During Pregnancy and/or LactationIpsen · recruiting · Pregnancy Related · study director
- N/ANCT06253897 · A Study to Understand Participant's Experiences in Gastro-enteropancreatic Neuroendocrine Tumors (GEP-NETs) and AcromegalyIpsen · completed · Gastro-enteropancreatic Neuroendocrine Tumor, Acromegaly · study director
- N/ANCT06245772 · CARegiver BURden, Effectiveness and Other Health Care Measures on Functional Disability, in Patients Treated With Abobotulinumtoxin A for Upper Limb SpasticityIpsen · active not recruiting · Upper Limb Injury · study director
- N/ANCT06089616 · A Study to Document and to Further Describe Long-term Safety and Effectiveness of Palovarotene in Participants With Fibrodysplasia Ossificans Progressiva (FOP)Ipsen · recruiting · Fibrodysplasia Ossificans Progressiva · study director
- Ph2NCT06068881 · A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic MutationEpizyme, Inc. · withdrawn · Follicular Lymphoma, Refractory Follicular Lymphoma · study director
- N/ANCT06055725 · A Study to Estimate How Often Post-stroke Spasticity Occurs and to Provide a Standard Guideline on the Best Way to Monitor Its DevelopmentIpsen · active not recruiting · Spasticity as Sequela of Stroke · study director
- Ph3NCT06047457 · A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in AdultsIpsen · active not recruiting · Episodic Migraine · study director
- Ph3NCT06047444 · A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in AdultsIpsen · active not recruiting · Chronic Migraine · study director
- Ph3NCT06016842 · A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary CholangitisIpsen · recruiting · Primary Biliary Cholangitis (PBC) · study director
- N/ANCT05922579 · A Study to Collect the Somatuline® Injector Device Preferences of Patients Living With Neuroendocrine Tumor (NET) and Nurses Involved in the Care of Patients With NETIpsen · terminated · Neuroendocrine Tumors · study director
- N/ANCT05759273 · A Study to Observe Demography and the Outcome of Prostate Cancer Patients Treated With 6-month Triptorelin Formulation in ItalyIpsen · completed · Prostate Cancer · study director
- Ph2NCT05642468 · Safety and Tolerability of A3907 in Primary Sclerosing CholangitisAlbireo, an Ipsen Company · terminated · Primary Sclerosing Cholangitis · study director
- Ph2NCT05627362 · A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.Ipsen · active not recruiting · Primary Sclerosing Cholangitis · study director
- Ph3NCT05590793 · Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the ProstateIpsen · completed · Advanced Prostate Cancer, Metastatic Prostate Cancer, Locally Advanced Prostate Cancer · study director
- N/ANCT05546190 · A Study to Collect Participants Experience of Living With Adult Upper Limb (AUL) Spasticity and to Assess the Arm Activity Measure (ArmA)Ipsen · completed · Spastic Hemiparesis, Muscle Spasticity · study director
- Ph1NCT05543369 · Study to Compare the Level of Elafibranor in Blood After Repeat Administration in Japanese and Non-Asian Healthy ParticipantsIpsen · completed · Healthy Volunteers · study director
- Ph3NCT05458856 · Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the ProstateIpsen · completed · Prostate Cancer · study director
- N/ANCT05444933 · A Study to Collect Pre-existing Data on the Administration of Cabozantinib in Participants With Advanced Renal Cell Carcinoma (aRCC) Who Initiated Cabozantinib in 2nd Line in a Real-life Clinical Setting in France.Ipsen · completed · Advanced Renal Cell Carcinoma · study director
- N/ANCT05431803 · Real-World Study (RWS) of Lanreotide Autogel (LAN) for the Treatment of Patients With Acromegaly in ChinaIpsen · completed · Acromegaly · study director
- Ph1NCT05383352 · A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the PancreasIpsen · completed · Metastatic Pancreatic Adenocarcinoma · study director
- N/ANCT05377684 · Study of Quality of Life and Hormone Levels in Premenopausal Participants With Early Breast Cancer Receiving Triptorelin Plus Additional Cancer TreatmentIpsen · completed · Early-stage Breast Cancer · study director
- N/ANCT05361434 · A Study of the Effectiveness of Cabozantinib in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma (aRCC) in AdultsIpsen · completed · Advanced Renal Cell Carcinoma · study director
- N/ANCT05224349 · Effectiveness and Safety of SMART [Spastic Muscle Palpation by Anatomic Landscape for BoNT-A (Botulinumtoxin-A) Injection to Reduce Muscle Tone] BoNT-A Therapy With Dysport® in Patients With Post-stroke Chronic Upper Limb Spasticity (ULS) in Real-life Setting.Ipsen · completed · Post-Stroke Chronic Upper Limb Spasticity · study director
- Ph1/Ph2NCT05205252 · A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.Epizyme, Inc. · withdrawn · Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy · study director
- N/ANCT05169775 · A Single Centre, Prospective, Observational Study to Assess the Use of the Rehabilitation Tool, GripAble, in Patients With Upper Limb Spasticity Receiving Botulinum Toxin-A (BoNT-A) in the United Kingdom (UK).Ipsen · completed · Upper Limb Spasticity (ULS) · study director
- Ph1NCT05121103 · A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell LymphomaEpizyme, Inc. · terminated · Multiple Myeloma, Refractory, Diffuse Large B-Cell Lymphoma, Diffuse Large B Cell Lymphoma Refractory · study director
- Ph2NCT05039515 · A Study to Assess the Effectiveness and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP).Clementia Pharmaceuticals Inc. · terminated · Fibrodysplasia Ossificans Progressiva · study director
- Ph3NCT05035030 · Long-term Safety and Efficacy of Odevixibat in Patients With Alagille SyndromeAlbireo, an Ipsen Company · active not recruiting · Alagille Syndrome · study director
- Ph3NCT05029622 · A Study to Assess the Efficacy and Safety of the Triptorelin 6-month Formulation in Paediatric Participants With Central Precocious Puberty.Ipsen · completed · Central Precocious Puberty · study director
- Ph3NCT05027802 · A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies.Ipsen · completed · Fibrodysplasia Ossificans Progressiva (FOP) · study director
- Ph1NCT04970407 · A Comparative Study to Evaluate the Effects and Mechanism of Action of Dysport®, Botox® and Xeomin® in the Extensor Digitorum Brevis Model in Healthy Adult Male ParticipantsIpsen · completed · Healthy Participants · study director
- N/ANCT04957160 · Cabozantinib Post First-line Immuno-oncology Checkpoint Inhibitor Containing CombinationIpsen · completed · Advanced Renal Cell Carcinoma (aRCC) · study director
- Ph4NCT04936542 · A Study to Compare the Safety and Efficacy of Dysport® and Botox® in Adults With Upper Limb Spasticity.Ipsen · completed · Upper Limb Spasticity · study director
- Ph3NCT04852679 · Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETsIpsen · completed · Gastroenteropancreatic Neuroendocrine Tumor · study director
- Ph1NCT04829786 · Study to Compare the Pharmacokinetics, Safety, and Tolerability Following Administration of Palovarotene in Healthy Japanese and Non-Asian SubjectsClementia Pharmaceuticals Inc. · completed · FOP · study director
- Ph1NCT04829773 · Study Evaluating the Effect of Food on the Pharmacokinetics of Palovarotene and the Effect of Palovarotene on the Pharmacokinetics of the CYP3A4 Substrate Midazolam in Two Cohorts of Healthy Adult SubjectsClementia Pharmaceuticals Inc. · completed · Fibrodysplasia Ossificans Progressiva · study director
- Ph1/Ph2NCT04821089 · A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Moderate to Severe Upper Facial LinesIpsen · active not recruiting · Moderate to Severe Upper Facial Lines · study director
- Ph1NCT04762355 · Study to Assess Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Palovarotene Ophthalmic Solution in Healthy Adult SubjectsClementia Pharmaceuticals Inc. · completed · Dry Eye Disease · study director
- Ph2NCT04762160 · SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular LymphomaEpizyme, Inc. · terminated · Follicular Lymphoma · study director
- Ph1/Ph2NCT04752774 · A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.Ipsen · recruiting · Spasticity · study director
- Ph3NCT04736602 · Efficacy and Safety Study of Triptorelin 3-Month Formulation in Chinese Children With Central Precocious Puberty.Ipsen · completed · Central Precocious Puberty · study director
- Ph1NCT04736745 · Study to Evaluate the Safety and Efficacy of IPN59011 in Improving the Appearance of Moderate to Severe Upper Facial Lines.Ipsen · terminated · Moderate Upper Facial Lines, Severe Upper Facial Lines · study director
- N/ANCT04665323 · An International Cross-sectional Survey to Evaluate the Burden of Fibrodysplasia Ossificans Progressiva (FOP) on Patients and Their Families.Ipsen · completed · Fibrodysplasia Ossificans Progressiva · study director
- N/ANCT04649580 · United Kingdom (UK) Patient Preference Study of Somatuline Autogel and Treatment Administration SettingIpsen · completed · Neuroendocrine Tumours (NET) · study director
- N/ANCT04649632 · Relation Between Dose and Time to Reinjection of Botulinum Toxin-A in Patient With Poststroke Spasticity From a Real-world Healthcare Insurance Database.Ipsen · completed · Post Stroke Spasticity · study director
- N/ANCT04637204 · Real-world Treatment Patterns and Outcomes Among aRCC Patients on Cabozantinib or Axitinib in EnglandIpsen · completed · Renal Cell Carcinoma · study director
- Ph1NCT04632199 · Study to Assess the Safety and Efficacy of Intravenous Injection of the Imaging Agent 111In-IPN01087 in Patients With Locally Advanced or Metastatic Pancreatic or Colorectal Cancer.Ipsen · withdrawn · Pancreatic Ductal Adenocarcinoma, Colorectal Cancer · study director
- N/ANCT04609800 · Study on the Utilization of Cabozantinib in Adult Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC) in 2nd Line Treatment Following Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy Under Real-real Life Clinical Setting in France.Ipsen · withdrawn · Renal Cell Carcinoma · study director
- N/ANCT04604379 · A Study to Review Treatment Outcomes From Treatment With Dysport® Injections in Adults for Upper and/or Lower Limb Focal SpasticityIpsen · completed · Upper and/or Lower Limb Focal Spasticity · study director
- N/ANCT04593420 · Treatment of Aggressive Prostate Cancer in Real Life: Initiation, Schedule and Management of Triptorelin Treatment.Ipsen · completed · Prostate Cancer · study director
- Ph3NCT04526665 · Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)Ipsen · active not recruiting · Primary Biliary Cirrhosis · study director
- N/ANCT04483531 · Odevixibat for the Treatment of Progressive Familial Intrahepatic CholestasisAlbireo · no longer available · Progressive Familial Intrahepatic Cholestasis · study director
- N/ANCT04446702 · Retrospective Real-Life Study From One Brazilian Reference Center Assessing Long-Term Experience In The Treatment Of Adult Spasticity With AbobotulinumtoxinAIpsen · completed · Spasticity · study director
- N/ANCT04396704 · A Study to Assess Treatment Outcomes of abobotulinumtoxinA and onabotulinumtoxinA Treatments in Real Life Practice in Toxin-naïve Adult Patients With Limb Spasticity.Ipsen · completed · Spasticity Related to Any Cause Except Cerebral Palsy · study director
- N/ANCT04353765 · Study Of Cabozantinib Treatment In Patients With Unresectable, Locally Advanced Or Metastatic Renal Cell Carcinoma Who Progressed After Previous Treatment With Checkpoint InhibitorsIpsen · completed · Locally Advanced or Metastatic Renal Cell Carcinoma · study director
- N/ANCT04340336 · Study Assessing Adult Subjects Affected With Upper and/or Lower Limb Spasticity Treated With Botulinum Neurotoxin Type AIpsen · completed · Spasticity · study director
- Ph3NCT04336722 · Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE (BOLD)Albireo, an Ipsen Company · completed · Biliary Atresia · study director
- Ph1/Ph2NCT04243499 · First-in-Human Study of ICT01 in Patients With Advanced CancerImCheck Therapeutics, an Ipsen company · active not recruiting · Solid Tumor, Adult, Hematopoietic/Lymphoid Cancer · study director
- Ph1NCT04241835 · A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver FunctionEpizyme, Inc. · terminated · Hepatic Impairment, Advanced Malignant Solid Tumor · study director
- Ph3NCT04224493 · A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.Epizyme, Inc. · active not recruiting · Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma · study director
- N/ANCT04225429 · Tazemetostat Expanded Access Program for Adults With Epithelioid SarcomaEpizyme, Inc. · no longer available · Epithelioid Sarcoma · study director
- Ph1NCT04204941 · Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid SarcomaEpizyme, Inc. · terminated · Advanced Soft-tissue Sarcoma, Advanced Epithelioid Sarcoma · study director
- Ph1/Ph2NCT04179864 · A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate CancerEpizyme, Inc. · terminated · Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer · study director
- N/ANCT04106349 · Observational Real-life Study of Cabozantinib in Monotherapy or in Combination With Nivolumab in Advanced Renal Cell Carcinoma (RCC)Ipsen · active not recruiting · Advanced or Metastatic Renal Cell Carcinoma · study director
- Ph3NCT04083235 · A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine TreatmentIpsen · completed · Metastatic Adenocarcinoma of the Pancreas · study director
- N/ANCT04050527 · Study to Assess the Effectiveness of AboBoNT-A Injections for Adult Lower Limb Spasticity in a Real Life CohortIpsen · completed · Adult Lower Limb Spasticity · study director
- N/ANCT04003519 · Study to Predict Lanreotide-induced Disease Activity Normalization in AcromegalyIpsen · withdrawn · Acromegaly · study director
- N/ANCT03995524 · Spasticity and Treatment Satisfaction Among Stroke SurvivorsIpsen · completed · Spasticity as Sequela of Stroke · study director
- N/ANCT03947762 · Lanreotide 120mg Effectiveness in Subjects With Pancreatic Neuroendocrine Tumours (PanNET) in Routine Clinical Practice.Ipsen · terminated · Pancreatic Neuroendocrine Tumor · study director
- Ph2NCT03945773 · Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint InhibitorsIpsen · completed · Locally Advanced or Metastatic Renal Cell Carcinoma · study director
- N/ANCT03895463 · Study to Assess the Use of Lanreotide Autogel® 120 mg in Patients With Locally Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) in Routine Clinical PracticeIpsen · withdrawn · Neuroendocrine Tumors · study director
- Ph1NCT03894540 · Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid TumoursIpsen · terminated · Solid Tumor · study director
- N/ANCT03874455 · Tazemetostat Expanded Access Program for Adults With Solid TumorsEpizyme, Inc. · no longer available · Epithelioid Sarcoma (Ex-US Only), Spindle Cell Sarcoma, Sinonasal Carcinoma · study director
- N/ANCT03846687 · Validation of Patient Reported Outcome Measures for Use in Hallux ValgusIpsen · completed · Hallux Valgus · study director
- N/ANCT03837678 · Epithelioid Sarcoma Natural History StudyEpizyme, Inc. · completed · Epithelioid Sarcoma · study director
- N/ANCT03776123 · Post-marketing Surveillance on the Safety of CabometyxTM in Korean PatientsIpsen · completed · Renal Cell Carcinoma, Hepatocellular Carcinoma, Differentiated Thyroid Carcinoma · study director
- Ph1/Ph2NCT03773133 · Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga-OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 (SSTR2)Ipsen · terminated · Small Cell Lung Cancer and Breast Cancer · study director
- N/ANCT03770169 · Validation of Patient Reported Outcome Measures for Use in VulvodyniaIpsen · completed · Vulvodynia · study director
- N/ANCT03744585 · Cabozantinib Real-life Use for Advanced Renal Cell Carcinoma in France: a Retrospective Descriptive Non-interventional Study of 2 Cohorts.Ipsen · completed · Renal Cell Carcinoma · study director
- N/ANCT03699579 · Pharmaco-Economic Study of Treatment Options in Patients With Advanced RCCIpsen · completed · Renal Cell Carcinoma Metastatic, Renal Cell Carcinoma · study director
- Ph2NCT03697551 · Define the Optimal Uptake Time of 68Ga-OPS202 When Used as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Newly Diagnosed Breast CancerIpsen · terminated · Breast Cancer · study director
- N/ANCT03696407 · A Non-interventional Retrospective Study to Describe Early Clinical Experience With Cabozantinib in Patients With Advanced Renal Cell Carcinoma (RCC) in the UKIpsen · completed · Advanced Renal Cell Carcinoma · study director
- N/ANCT03689673 · Study of the Effectiveness of ETIASA® (Sustained Release 5-Aminosalicylate) in Maintenance Treatment of Ulcerative Colitis (UC)Ipsen · completed · Ulcerative Colitis · study director
- Ph2NCT03663101 · Dysport in Post-Surgical NeuralgiaIpsen · completed · Chronic Scar Pain · study director
- Ph3NCT03659916 · Long Term Safety & Efficacy Study Evaluating The Effect of A4250 in Children With PFICAlbireo, an Ipsen Company · completed · Progressive Familial Intrahepatic Cholestasis · study director
- N/ANCT03647878 · Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment.Ipsen · active not recruiting · Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma · study director
- Ph1NCT03608319 · Study of A4250 in Healthy Volunteers Under Fasting, Fed and Sprinkled ConditionsAlbireo · completed · Healthy Volunteers · study director
- Ph2NCT03598777 · Dysport in Vulvodynia Phase II StudyIpsen · terminated · Vulvodynia · study director
- Ph2NCT03569098 · Dysport in Hallux Abducto Valgus (HAV) Phase IIaIpsen · completed · Hallux Abducto Valgus · study director
- Ph3NCT03562884 · Efficacy, Safety and Tolerability of a New Bowel Cleansing Preparation (BLI800) in Adult Subjects Undergoing ColonoscopyIpsen · completed · Diagnosis Disease · study director
- N/ANCT03562091 · Perception of Information and Quality of Life in Neuroendocrine Tumour on Lanreotide AutogelIpsen · completed · Neuroendocrine Tumors · study director
- Ph1NCT03525392 · Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.Ipsen · terminated · Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Gastric Cancer · study director
- N/ANCT03516110 · Health Related Quality of Life and Multidimensional Evaluations of Prostate Cancer Subjects Aged ≥ 60 Years Initiating Gonadotropin-Releasing Hormone (GNRH) Agonist TherapyIpsen · completed · Prostate Cancer · study director
- Ph2NCT03442985 · An Efficacy and Safety Study of Palovarotene for the Treatment of MOClementia Pharmaceuticals Inc. · terminated · Exostoses, Multiple Hereditary · study director
- Ph1NCT03442725 · Study to Compare a Dose of Telotristat Etiprate in Subjects With Renal Impairment With Matched Subjects With Normal Renal FunctionIpsen · completed · Renal Impairment · study director
- N/ANCT03442660 · Validation of the Spasticity Related Quality of Life QuestionnaireIpsen · completed · Spasticity, Muscle · study director
- N/ANCT03419572 · Non-interventional Study of Cabozantinib in Adults With Advanced Renal Cell CarcinomaIpsen · completed · Renal Cell Carcinoma · study director
- Ph3NCT03312634 · An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva.Clementia Pharmaceuticals Inc. · completed · Fibrodysplasia Ossificans Progressiva · study director
- Ph3
- Ph2NCT03220217 · To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)Ipsen · completed · Gastro-Enteropancreatic Neuroendocrine Tumor · study director
- N/ANCT03220087 · Study to Evaluate the Use of Resources and the Costs Associated With Carcinoid Syndrome (CS) in Patients With NETs in SpainIpsen · completed · Neuroendocrine Tumors · study director
- N/ANCT03112694 · Switching From Octreotide to Lanreotide - A Look Back at Patients With Neuroendocrine TumorsIpsen · completed · Neuroendocrine Tumors · study director
- Ph3NCT03088813 · Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung CancerIpsen · completed · Small Cell Lung Cancer · study director
- Ph1NCT03082937 · An Open Label, Single-dose, Single Period ADME Study of A4250 in Healthy SubjectsAlbireo · completed · Orphan Cholestatic Liver Diseases, Progressive Familial Intrahepatic Cholestasis, Alagille Syndrome · study director
- Ph1NCT03045926 · Chronic Administration of Diosmectite (SMECTA®) in Subjects With Chronic DiarrhoeaIpsen · completed · Chronic Functional Diarrhea of Unknown Origin · study director
- N/ANCT03017313 · To Evaluate the Criteria for Renewal of Luteinizing Hormone-Releasing Hormone (LHRH) Analogue Treatment in Prostate Cancer PatientsIpsen · completed · Prostate Cancer · study director
- N/ANCT03017690 · Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)Ipsen · completed · Gastroenteropancreatic Neuroendocrine Tumor · study director
- N/ANCT03017729 · Effectiveness and Safety of Dysport® (abobotulinumtoxinA) in Paediatric Lower Limb SpasticityIpsen · completed · Lower Limb Spasticity · study director
- Ph1NCT03010982 · Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid TumorsEpizyme, Inc. · completed · Diffuse Large B Cell Lymphoma, Primary Mediastinal Lymphoma, Mantle-Cell Lymphoma · study director
- Ph3NCT03008460 · Efficacy, Safety and Tolerability of Eziclen®/Izinova® Versus Klean-prep® on Bowel Cleansing in Adolescents Undergoing ColonoscopyIpsen · completed · Digestive System Disease · study director
- Ph4NCT02969356 · Study to Evaluate Effects of DYSPORT® Injected in Lower and Upper Limb Combined With Guided Self-Rehabilitation Contract (GSC)Ipsen · completed · Spastic Hemiparesis · study director
- Ph1NCT02963077 · A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384Albireo · completed · Orphan Cholestatic Liver Diseases, Primary Biliary Cirrhosis, Progressive Familial Intrahepatic Cholestasis · study director
- Ph1/Ph2NCT02875548 · A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical StudyEpizyme, Inc. · terminated · Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Synovial Sarcoma · study director
- N/ANCT02853422 · Quality-Of-Life QLQ-GINET21 Questionnaire In The Treatment Of Patients With Gastrointestinal Neuroendocrine TumoursIpsen · completed · Gastrointestinal Neuroendocrine Tumours · study director
- N/ANCT02853409 · Quality of Life of Patients With Locally Advanced and Metastatic Prostate CancerIpsen · completed · Prostate Cancer · study director
- N/ANCT02807233 · Lanreotide Autogel 120 mg at Extended Dosing Intervals (>4 Weeks) in Acromegalic SubjectsIpsen · completed · Acromegaly · study director
- N/ANCT02788578 · A Retrospective Data Analysis of Therapy With PRRT Combined With Lanreotide Autogel® for Neuroendocrine TumoursIpsen · terminated · Neuroendocrine Tumours · study director
- N/ANCT02788565 · Quality of Life, Treatment Experience and Cost of Treatment With Somatostatin Analogues in Patients With Gastroenteropancreatic Neuroendocrine TumoursIpsen · completed · Gastroenteropancreatic Neuroendocrine Tumours · study director
- N/ANCT02730104 · Community-based Neuroendocrine Tumor (NET) Research StudyIpsen · completed · Gastroenteropancreatic Neuroendocrine Tumors · study director
- Ph4NCT02704091 · Efficacy of Diosmectite (Smecta®) in the Symptomatic Treatment of Acute Diarrhoea in AdultsIpsen · completed · Acute Diarrhoea · study director
- Ph2NCT02698410 · Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors.Ipsen · completed · Neuroendocrine Tumours · study director
- N/ANCT02698384 · Therapeutic Strategies in Acromegalic Subjects Treated With Lanreotide 120mgIpsen · terminated · Acromegaly · study director
- Ph1NCT02683577 · Study to Evaluate a Dose of Telotristat Etiprate in Male and Female With Mild, Moderate and Severe Hepatic Insufficiency and Matched Healthy SubjectsIpsen · completed · Hepatic Impairment · study director
- Ph3NCT02683941 · Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine TumoursIpsen · terminated · Neuroendocrine Tumors in Lung · study director
- Ph3NCT02660359 · Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2Ipsen · terminated · Urinary Incontinence, Overactive Bladder · study director
- Ph3NCT02660138 · Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1Ipsen · terminated · Urinary Incontinence, Overactive Bladder · study director
- Ph2NCT02651987 · Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mgIpsen · completed · Pancreatic Tumours, Midgut Neuroendocrine Tumours · study director
- N/ANCT02630654 · Study For Evaluating The Value Of A Multi Biomarker Approach In Metastatic GEP NETsIpsen · completed · Gastroenteropancreatic Neuroendocrine Tumors · study director
- N/ANCT02630680 · Eziclen Drug Utilisation in Real Life SettingIpsen · completed · Bowel Cleansing · study director
- N/ANCT02630641 · Perception of Cohesion Within a Relationship (Dyadic Adjustment) on the Quality of Life of Patients With Prostate Cancer With Gonadotropin-releasing Hormone.Ipsen · completed · Prostate Cancer · study director
- Ph2NCT02630875 · A4250, an IBAT Inhibitor in Pediatric CholestasisAlbireo · completed · Pediatric Cholestasis · study director
- Ph2NCT02601950 · A Study of Tazemetostat in Adult Participants With Soft Tissue SarcomaEpizyme, Inc. · completed · Malignant Rhabdoid Tumors (MRT), Rhabdoid Tumors of the Kidney (RTK), Atypical Teratoid Rhabdoid Tumors (ATRT) · study director
- Ph1/Ph2NCT02592707 · Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETsIpsen · terminated · Neuroendocrine Tumors · study director
- Ph2NCT02551991 · Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic AdenocarcinomaIpsen · completed · Pancreatic Cancer · study director
- N/ANCT02542501 · Study to Evaluate the Presence of Lower Urinary Tract Symptoms (LUTS) in Prostate Cancer Patients Scheduled to Receive Luteinizing Hormone Releasing Hormone (LHRH) AnaloguesIpsen · completed · Prostate Cancer · study director
- N/ANCT02539927 · Validation Study of the SAGIT® Instrument in AcromegalyIpsen · completed · Acromegaly · study director
- Ph2NCT02521792 · In-Home Evaluation of Episodic Administration of Palovarotene in Fibrodysplasia Ossificans Progressiva (FOP) SubjectsClementia Pharmaceuticals Inc. · terminated · Fibrodysplasia Ossificans Progressiva · study director
- Ph3NCT02493517 · Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in AcromegalyIpsen · completed · Acromegaly · study director
- N/ANCT02454803 · Attainment of Person-centred Goals After Botulinum Toxin Treatment for Upper Limb Spasticity in Real Life PracticeIpsen · completed · Upper Limb Spasticity · study director
- N/ANCT02444494 · Study to Document the Effectiveness of Dysport in Patients Suffering From Upper Limb Spasticity (ULS) After StrokeIpsen · completed · Post Stroke Arm Spasticity · study director
- Ph1/Ph2NCT02396953 · Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With AcromegalyIpsen · completed · Acromegaly · study director
- N/ANCT02396966 · Quality of Life (QoL) in Subjects With Acromegaly Under Lanreotide Autogel® Treatment.Ipsen · completed · Acromegaly · study director
- N/ANCT02384330 · Botulinum Toxin A Associated Costs in the Treatment of Upper Limb Spasticity Post StrokeIpsen · completed · Upper Limb Spasticity Post-Stroke · study director
- Ph2NCT02365584 · Quality of Life in Patients With Inoperable Malignant Bowel ObstructionIpsen · terminated · Intestinal Obstruction · study director
- N/ANCT02353897 · Patient and Physician's Satisfaction After a Long Term Treatment of Glabellar Lines With Dysport®Ipsen · completed · Glabellar Lines · study director
- N/ANCT02322255 · A Natural History Study of Fibrodysplasia Ossificans Progressiva (FOP)Clementia Pharmaceuticals Inc. · completed · Fibrodysplasia Ossificans Progressiva · study director
- Ph4NCT02321436 · Study to Assess Impact of Dysport Injections Early After Stroke on Upper Limb Spasticity ProgressionIpsen · completed · Stroke, Upper Limb Spasticity · study director
- N/ANCT02321475 · EGb 761® (Tanakan®) Effectiveness in the Treatment of Patients of Middle Age and Younger With Psycho-emotional Symptoms, Added to Cognitive DisordersIpsen · completed · Cognitive Disorders · study director
- N/ANCT02321449 · The Effectiveness of Circadin in Improving Quality of Sleep in Patients Aged 55 or OverIpsen · completed · Insomnia · study director
- Ph3NCT02321462 · Efficacy, Safety and Tolerability of Eziclen in Adult Subjects Undergoing ColonoscopyIpsen · completed · Bowel Cleansing · study director
- Ph2NCT02279095 · An Open-Label Extension Study of Palovarotene Treatment in Fibrodysplasia Ossificans Progressiva (FOP)Clementia Pharmaceuticals Inc. · completed · Fibrodysplasia Ossificans Progressiva · study director
- N/ANCT02275312 · ETREAT Study on Effectiveness of Botulinum Toxin Type A Injections to Treat Post-stroke Upper and/or Lower Limb SpasticityIpsen · completed · Spasticity · study director
- Ph2NCT02275338 · Study to Assess Efficacy and Safety of Lanreotide Autogel 120 MG in Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal ObstructionIpsen · completed · Intestinal Obstruction · study director
- N/ANCT02238366 · Study To Assess Renewal Of Treatment In Patients Recently Diagnosed With Prostate CancerIpsen · completed · Prostate Cancer · study director
- Ph2NCT02231762 · Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NETIpsen · completed · Gastroenteropancreatic Neuroendocrine Tumors · study director
- Ph2NCT02231580 · Study Exploring Safety, Pharmacokinetic and Pharmacodynamic of BN82451 in Male Huntington's Disease PatientsIpsen · terminated · Huntington's Disease · study director
- Ph2NCT02190747 · An Efficacy and Safety Study of Palovarotene to Treat Preosseous Flare-ups in FOP SubjectsClementia Pharmaceuticals Inc. · completed · Fibrodysplasia Ossificans Progressiva · study director
- Ph1/Ph2NCT02162446 · 68Ga-OPS202 Study for Diagnostic Imaging of GEP NETIpsen · completed · Gastroenteropancreatic Neuroendocrine Tumors · study director
- Ph3NCT02106351 · Efficacy And Safety Of Dysport In The Treatment Of Upper Limb Spasticity In ChildrenIpsen · completed · Upper Limb Spasticity (Altered Skeletal Muscle Performance) in Children · study director
- Ph2NCT02078856 · Double-blind, Randomised Study of A3384 in BAM/BADAlbireo · completed · Bile Acid Malabsorption · study director
- N/ANCT02020499 · Predictive Factors StudyIpsen · terminated · Acromegaly · study director
- N/ANCT02020967 · Programme of Acromegaly Screening in Patients With Associated Somatic DisordersIpsen · completed · Acromegaly · study director
- N/ANCT02020980 · RELIEF Study: Lower Limb Pain Relief After Injection Cycles in Adults Suffering From Lower Limb Spasticity Following StrokeIpsen · completed · Lower Limb Spasticity · study director
- N/ANCT02012036 · Study To Optimize Photodynamic Transurethral Resection of the Bladder (TUR-B) In Clinical PracticeIpsen · completed · Photodynamic Transurethral Resection of the Bladder (TUR-B) · study director
- N/ANCT02012127 · Description of Sign-and-symptom Associations at Acromegaly Diagnosis.Ipsen · completed · Acromegaly · study director
- N/ANCT01942369 · A Study to Describe the Efficacy of Diphereline Following Conservative Surgery in Deep Infiltrating Endometriosis (DIE) Patients Over a Period of 24 MonthsIpsen · completed · Deep Infiltrating Endometriosis (DIE) · study director
- Ph1/Ph2NCT01897571 · Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCLEpizyme, Inc. · completed · B-cell Lymphomas (Phase 1), Advanced Solid Tumors (Phase 1), Diffuse Large B-cell Lymphoma (Phase 2) · study director
- N/ANCT01840475 · Arm Spasticity - Non-Interventional Study Early BIRD (BoNT Treatment: Initial and Repeated Documentation)Ipsen · completed · Post-stroke Arm Spasticity · study director
- N/ANCT01840449 · Somatuline Predictive Factors in Acromegaly and NETIpsen · completed · Acromegaly, Neuroendocrine Tumours · study director
- N/ANCT01840462 · Longitudinal Study for Treatment With Botulinum Toxin A Injections in naïve and Pre-treated Patients Suffering From Cervical Dystonia [CD-NIS-Longterm]Ipsen · completed · Cervical Dystonia · study director
- Ph1NCT01770353 · MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to TreatmentIpsen · completed · Solid Tumors, ER/PR Positive Breast Cancer, Triple Negative Breast Cancer · study director
- Ph4NCT01753297 · A Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients.Ipsen · completed · Prostate Cancer · study director
- N/ANCT01753349 · Phase IV-Cervical Dystonia-INTEREST IN CD2Ipsen · completed · Cervical Dystonia · study director
- Ph2NCT01743469 · A Study With Tasquinimod Treating Patients With Hepatocellular, Ovarian, Renal Cell and Gastric CancersIpsen · completed · Advanced or Metastatic Hepatocellular Cancer, Advanced or Metastatic Ovarian Cancer, Metastatic Renal Cell Cancer · study director
- Ph2NCT01732549 · A Proof of Concept Study of Maintenance Therapy With Tasquinimod in Patients With Metastatic Castrate-resistant Prostate Cancer Who Are Not Progressing After a First Line Docetaxel Based ChemotherapyIpsen · terminated · Metastatic Castrate Resistant Prostate Cancer · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:57 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in osteosarcoma.